End-of-day quote
Other stock markets
|
||
- EUR | - |
May. 02 | Health Care Flat Amid Mixed Earnings -- Health Care Roundup | DJ |
May. 02 | Novo Nordisk, Eli Lilly's Weight-Loss Drugs Get Price Cuts in UK | MT |
Sales 2024 * | 287B 41.33B 38.48B | Sales 2025 * | 347B 49.9B 46.45B | Capitalization | 3,879B 558B 520B |
---|---|---|---|---|---|
Net income 2024 * | 103B 14.86B 13.84B | Net income 2025 * | 125B 18.03B 16.78B | EV / Sales 2024 * | 13.7 x |
Net Debt 2024 * | 53.94B 7.76B 7.23B | Net Debt 2025 * | 12.36B 1.78B 1.66B | EV / Sales 2025 * | 11.2 x |
P/E ratio 2024 * |
37.9
x | P/E ratio 2025 * |
31
x | Employees | - |
Yield 2024 * |
1.4% | Yield 2025 * |
1.62% | Free-Float | 70.17% |
Latest transcript on Novo Nordisk A/S
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 90-12-31 | |
Director of Finance/CFO | 53 | 98-12-31 | |
Stephen Gough
CTO | Chief Tech/Sci/R&D Officer | - | 15-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 63 | 15-03-18 |
Helge Lund
CHM | Chairman | 61 | 17-03-22 |
Martin MacKay
BRD | Director/Board Member | 68 | 18-02-28 |
1st Jan change | Capi. | |
---|---|---|
+29.68% | 699B | |
-4.35% | 364B | |
+17.65% | 326B | |
+3.77% | 286B | |
+14.68% | 236B | |
+4.71% | 198B | |
-12.43% | 194B | |
-3.79% | 154B | |
-3.34% | 149B |